GLP Watchdog

Hims vs Mochi Health

Hims has an open FDA warning letter dated September 9, 2025. Mochi Health has none. No price lines up like for like. They share brand-name semaglutide pen, but both price it at $199, and in each case that covers the medication only, with a separate membership on top.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hims / Mochi Health

Hims logo

Hims

6.7/10

Mochi Health logo

Mochi Health

7.1/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$149/moBrand-name semaglutide pill, medication only, membership extra
$110/moFoundayo (orforglipron) pill
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Hims
Visit Mochi Health

Neither Hims nor Mochi Health pays us. Links to them earn nothing. Scores: Hims 6.7, Mochi Health 7.1. How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. Mochi Health has none.

  2. 02

    Mochi Health names no compounding pharmacy in our record. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like. They share brand-name semaglutide pen, but both price it at $199, and in each case that covers the medication only, with a separate membership on top.

  4. 04

    Only Mochi Health lists a price for compounded semaglutide injection, compounded tirzepatide injection and compounded oral semaglutide.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hims

Mochi Health

Brand-name semaglutide pen

$199/mo

medication only, membership extra; not compared

$199/mo

medication only, membership extra; not compared

Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

$299/mo

medication only, membership extra; not compared

Brand-name semaglutide pill

$149/mo

medication only, membership extra; not compared

$149/mo

medication only, membership extra; not compared

Foundayo (orforglipron) pill

$149/mo

medication only, membership extra; not compared

$110/mo

$1,320 a year

Compounded semaglutide injection
Not sold or not priced

$139/mo

plan terms unclear; not compared

Compounded tirzepatide injection
Not sold or not priced

$169/mo

plan terms unclear; not compared

Compounded oral semaglutide
Not sold or not priced

$141/mo

$1,692 a year

Price includes
Medication
Clinician visits, coaching
Billed separately
Clinician visits, coaching
Medication
Cancel any time
Yes, stated
Yes, stated
Minimum term
Monthly membership, auto-renews
None on the monthly plan; 3, 6 and 12-month memberships are prepaid
Refunds
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
No refunds for partly used periods; medication is not refundable once sent to the pharmacy
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Hims: October 17, 2026. Mochi Health: October 31, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hims

6.7/10

The record gives Hims no edge on this pair.

  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

The case for Mochi Health

7.1/10
  • No FDA warning letter on record
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Hims does not price
  • Price includes clinician visits and coaching
  • Names no compounding pharmacy
  • Price leaves out medication
Visit Mochi Health

Scores

Hims 6.7 · Mochi Health 7.1 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
7.5

Trust & Safety15%

6.0A
vs
B
8.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

3.0A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

Hims vs Mochi Health: questions

Hims has an open FDA warning letter dated September 9, 2025. Mochi Health has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Mochi Health names no compounding pharmacy in our record. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like. They share brand-name semaglutide pen, but both price it at $199, and in each case that covers the medication only, with a separate membership on top. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed. Mochi Health states you can cancel at any time; refunds: no refunds for partly used periods; medication is not refundable once sent to the pharmacy.
Neither Hims nor Mochi Health pays us. Links to them earn nothing. Scores: Hims 6.7, Mochi Health 7.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks